Imugene doses first patient in HER-Vaxx phase 2 trial
Filed with ASX · · 3 pages · English
Story so far
Earlier from Imugene
- IMU Announces Presentations on KEY-Vaxx and B-Vaxx at AACR
- Pause in Trading
- IMU Meets Endpoints in Phase 1b Gastric Cancer Trial
- Imugene Advances to Phase 2 in Gastric Cancer Trial
- Imugene Receives $1.85 million R&D Tax Incentive
Later from Imugene
- IMU Pre-IND FDA Meeting Provides Guidance for KEY-Vaxx
- IMU presents new KEY-Vaxx and B-Vaxx data at AACR
- IMU presents new mimotope PD-1 vaccine data at AACR
- Appendix 4C - Quarterly and Business Update
- New HER-Vaxx Cancer Vaccine trial data presented at ESMO GI
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene